(Johnson & Johnson) Vaccine maker Johnson & Johnson expects $2.5 billion sales in its Covid-19 vaccine amidst doubts of its effectiveness against the delta variant.
The company reported $23.31 billion in revenue in the second quarter, an equivalent of $2.48 EPS, more than a forecast of $22.21 billion or $2.27 EPS.
The reported sales are an increase of 27.1% compared to $18.336 billion reported in the second quarter of 2020.
The sales of the Covid-19 vaccine globally by the company was $164 million in the second quarter of 2021.
J&J has expressed optimism that it will report a full-year profit of between $ 9.5-$9.6 EPS and a revenue target of up to $93.3 billion.
Previous full year EPS forecast was $9.30-$9.45, while revenues were $89.3 billion-$90.3 billion.
JNJ: NYSE is down -0.49% on pre-market.
